8-KMaterial AgreementsOther EventsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Material Agreement (Aug 1, 2018)

Filed August 1, 2018For Securities:ONCBEIGF

Summary

This 8-K filing from BeiGene, Ltd. (ONC) announces a proposed underwritten global offering of ordinary shares, including a Hong Kong public offering and a global offering. The company aims to list its ordinary shares on The Stock Exchange of Hong Kong Limited (SEHK) under the stock code '06160', while its American Depositary Shares (ADSs) remain listed on NASDAQ under 'BGNE'. This dual listing strategy is a significant development for the company, potentially broadening its investor base and access to capital. The offering details, including the number of shares, expected price range, and the option for additional shares, are provided, with an expected closing date of August 8, 2018, subject to market conditions and customary closing conditions. Investors should note that the filing includes standard cautionary statements regarding the forward-looking nature of the offering details. The company has entered into a Hong Kong Underwriting Agreement with several major financial institutions. While the filing provides key details of the material definitive agreement, investors are advised to refer to the full agreement and other public disclosures for comprehensive information, as representations and warranties within underwriting agreements may not always align with investor disclosure standards.

Key Highlights

  • 1BeiGene, Ltd. (ONC) announced a proposed underwritten global offering of ordinary shares.
  • 2The offering includes a Hong Kong public offering and a global offering.
  • 3Company intends to list its ordinary shares on The Stock Exchange of Hong Kong Limited (SEHK) under stock code '06160'.
  • 4This will result in a dual listing, with ADSs remaining on NASDAQ under 'BGNE'.
  • 5Expected offering price range is HK$94.40-HK$111.60 per share (approx. US$12.03-US$14.22).
  • 6Joint global coordinators have an option to purchase up to 9,840,000 additional ordinary shares.
  • 7The offering is subject to market conditions and customary closing conditions, expected to close around August 8, 2018.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce BeiGene, Ltd.'s proposed underwritten global offering of ordinary shares and its intention to list these shares on The Stock Exchange of Hong Kong Limited (SEHK), creating a dual listing.

A dual listing allows BeiGene to broaden its investor base by accessing capital markets in both Asia and North America. It enhances accessibility for investors in different regions and can potentially increase liquidity for the company's securities.

The offering is expected to close on August 8, 2018, subject to market and other conditions. The preliminary expected price range for the shares is between HK$94.40 and HK$111.60 per share, which translates to approximately US$12.03 to US$14.22 per share.

Investors should be aware that the offering is subject to market conditions and customary closing conditions, meaning it may not be completed as planned or on the anticipated terms. The filing also contains standard cautionary language about forward-looking statements, and investors are advised to consult the company's other SEC filings for a comprehensive understanding of risks.